PTC Therapeutics Q2 FY26 net income swings to $83.5 million; revenue more than doubles to $361 million - PTCT News | RalliesPTC Therapeutics Q2 FY26 net income swings to $83.5 million; revenue more than doubles to $361 million
P
PTCT• Q2 results and product revenue
- PTC Therapeutics posted Q2 total revenue of USD 361 million, more than doubled from a year earlier; net income swung to USD 83.5 million.
- Net product revenue more than doubled to USD 238.8 million, while royalty revenue rose to USD 71.1 million.
- Sephience revenue climbed 21% from Q1 to USD 151.3 million, with 1,647 patients on commercial therapy worldwide.
- Translarna revenue fell to USD 42.2 million; Emflaza dropped to USD 24.6 million due to continued generic erosion.
2026 outlook
- 2026 total revenue outlook increased to USD 1.18 billion–USD 1.28 billion; product revenue guidance raised to USD 850 million–USD 950 million.
•
